Logo image of TBPH

THERAVANCE BIOPHARMA INC (TBPH) Stock Fundamental Analysis

NASDAQ:TBPH - Nasdaq - KYG8807B1068 - Common Stock - Currency: USD

10.61  -0.12 (-1.12%)

After market: 10.61 0 (0%)

Fundamental Rating

3

Taking everything into account, TBPH scores 3 out of 10 in our fundamental rating. TBPH was compared to 195 industry peers in the Pharmaceuticals industry. While TBPH seems to be doing ok healthwise, there are quite some concerns on its profitability. TBPH is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year TBPH has reported negative net income.
In the past year TBPH had a positive cash flow from operations.
In the past 5 years TBPH reported 4 times negative net income.
TBPH had a negative operating cash flow in each of the past 5 years.
TBPH Yearly Net Income VS EBIT VS OCF VS FCFTBPH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M 800M

1.2 Ratios

Looking at the Return On Assets, with a value of -16.98%, TBPH is in the better half of the industry, outperforming 64.10% of the companies in the same industry.
Looking at the Return On Equity, with a value of -35.14%, TBPH is in line with its industry, outperforming 59.49% of the companies in the same industry.
Industry RankSector Rank
ROA -16.98%
ROE -35.14%
ROIC N/A
ROA(3y)37.73%
ROA(5y)0.15%
ROE(3y)46.45%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
TBPH Yearly ROA, ROE, ROICTBPH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400

1.3 Margins

TBPH does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TBPH Yearly Profit, Operating, Gross MarginsTBPH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K -1K

More info and screens

6

2. Health

2.1 Basic Checks

TBPH does not have a ROIC to compare to the WACC, probably because it is not profitable.
TBPH has more shares outstanding than it did 1 year ago.
TBPH has less shares outstanding than it did 5 years ago.
Compared to 1 year ago, TBPH has a worse debt to assets ratio.
TBPH Yearly Shares OutstandingTBPH Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
TBPH Yearly Total Debt VS Total AssetsTBPH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

TBPH has an Altman-Z score of -2.03. This is a bad value and indicates that TBPH is not financially healthy and even has some risk of bankruptcy.
TBPH has a Altman-Z score of -2.03. This is comparable to the rest of the industry: TBPH outperforms 48.21% of its industry peers.
The Debt to FCF ratio of TBPH is 0.96, which is an excellent value as it means it would take TBPH, only 0.96 years of fcf income to pay off all of its debts.
TBPH's Debt to FCF ratio of 0.96 is amongst the best of the industry. TBPH outperforms 95.38% of its industry peers.
A Debt/Equity ratio of 0.19 indicates that TBPH is not too dependend on debt financing.
The Debt to Equity ratio of TBPH (0.19) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.19
Debt/FCF 0.96
Altman-Z -2.03
ROIC/WACCN/A
WACC10.03%
TBPH Yearly LT Debt VS Equity VS FCFTBPH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

2.3 Liquidity

A Current Ratio of 4.77 indicates that TBPH has no problem at all paying its short term obligations.
With a decent Current ratio value of 4.77, TBPH is doing good in the industry, outperforming 68.72% of the companies in the same industry.
A Quick Ratio of 4.77 indicates that TBPH has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 4.77, TBPH is in the better half of the industry, outperforming 70.77% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.77
Quick Ratio 4.77
TBPH Yearly Current Assets VS Current LiabilitesTBPH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for TBPH have decreased strongly by -30.23% in the last year.
Looking at the last year, TBPH shows a small growth in Revenue. The Revenue has grown by 6.18% in the last year.
The Revenue has been decreasing by -2.59% on average over the past years.
EPS 1Y (TTM)-30.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-12.5%
Revenue 1Y (TTM)6.18%
Revenue growth 3Y5.2%
Revenue growth 5Y-2.59%
Sales Q2Q%6.1%

3.2 Future

TBPH is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 36.17% yearly.
The Revenue is expected to grow by 30.97% on average over the next years. This is a very strong growth
EPS Next Y68.74%
EPS Next 2Y2.72%
EPS Next 3Y18.85%
EPS Next 5Y36.17%
Revenue Next Year44.45%
Revenue Next 2Y12.91%
Revenue Next 3Y19.57%
Revenue Next 5Y30.97%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
TBPH Yearly Revenue VS EstimatesTBPH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M 400M
TBPH Yearly EPS VS EstimatesTBPH Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 5 -5 10

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

TBPH reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TBPH. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TBPH Price Earnings VS Forward Price EarningsTBPH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20

4.2 Price Multiples

TBPH's Price/Free Cash Flow ratio is rather cheap when compared to the industry. TBPH is cheaper than 86.15% of the companies in the same industry.
Industry RankSector Rank
P/FCF 16.43
EV/EBITDA N/A
TBPH Per share dataTBPH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3

4.3 Compensation for Growth

TBPH's earnings are expected to grow with 18.85% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y2.72%
EPS Next 3Y18.85%

More info and screens

0

5. Dividend

5.1 Amount

TBPH does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

THERAVANCE BIOPHARMA INC

NASDAQ:TBPH (6/11/2025, 8:21:30 PM)

After market: 10.61 0 (0%)

10.61

-0.12 (-1.12%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-08 2025-05-08/amc
Earnings (Next)08-04 2025-08-04
Inst Owners94.28%
Inst Owner Change0.66%
Ins Owners5.82%
Ins Owner Change2.71%
Market Cap530.50M
Analysts80
Price Target15.56 (46.65%)
Short Float %8.47%
Short Ratio14.16
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-30.41%
Min EPS beat(2)-44.72%
Max EPS beat(2)-16.1%
EPS beat(4)0
Avg EPS beat(4)-26.03%
Min EPS beat(4)-44.72%
Max EPS beat(4)-10.35%
EPS beat(8)2
Avg EPS beat(8)-14.88%
EPS beat(12)3
Avg EPS beat(12)-28.11%
EPS beat(16)5
Avg EPS beat(16)-26.92%
Revenue beat(2)1
Avg Revenue beat(2)2.46%
Min Revenue beat(2)-2.67%
Max Revenue beat(2)7.58%
Revenue beat(4)2
Avg Revenue beat(4)0.79%
Min Revenue beat(4)-9.55%
Max Revenue beat(4)7.78%
Revenue beat(8)4
Avg Revenue beat(8)-0.96%
Revenue beat(12)5
Avg Revenue beat(12)-4.23%
Revenue beat(16)6
Avg Revenue beat(16)-5.07%
PT rev (1m)23.65%
PT rev (3m)5.17%
EPS NQ rev (1m)6%
EPS NQ rev (3m)-12.8%
EPS NY rev (1m)0%
EPS NY rev (3m)-414.35%
Revenue NQ rev (1m)-0.04%
Revenue NQ rev (3m)-0.86%
Revenue NY rev (1m)-5%
Revenue NY rev (3m)5.16%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 8.13
P/FCF 16.43
P/OCF 16.31
P/B 3.2
P/tB 3.2
EV/EBITDA N/A
EPS(TTM)-1.12
EYN/A
EPS(NY)-1.03
Fwd EYN/A
FCF(TTM)0.65
FCFY6.09%
OCF(TTM)0.65
OCFY6.13%
SpS1.31
BVpS3.32
TBVpS3.32
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -16.98%
ROE -35.14%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM 49.47%
ROA(3y)37.73%
ROA(5y)0.15%
ROE(3y)46.45%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.19
Health
Industry RankSector Rank
Debt/Equity 0.19
Debt/FCF 0.96
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.77
Quick Ratio 4.77
Altman-Z -2.03
F-Score4
WACC10.03%
ROIC/WACCN/A
Cap/Depr(3y)20.39%
Cap/Depr(5y)43.25%
Cap/Sales(3y)1.99%
Cap/Sales(5y)4.27%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-30.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-12.5%
EPS Next Y68.74%
EPS Next 2Y2.72%
EPS Next 3Y18.85%
EPS Next 5Y36.17%
Revenue 1Y (TTM)6.18%
Revenue growth 3Y5.2%
Revenue growth 5Y-2.59%
Sales Q2Q%6.1%
Revenue Next Year44.45%
Revenue Next 2Y12.91%
Revenue Next 3Y19.57%
Revenue Next 5Y30.97%
EBIT growth 1Y-10.98%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y118.62%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y118.9%
OCF growth 3YN/A
OCF growth 5YN/A